 CA-19-9 Antigen
"CA-19-9 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
| Descriptor ID |
D018395
|
| MeSH Number(s) |
D23.050.285.050.119 D23.050.301.290.544.119 D23.050.550.325.119 D23.050.705.230.544.119 D23.101.140.075.119
|
| Concept/Terms |
CA-19-9 Antigen- CA-19-9 Antigen
- Antigen, CA-19-9
- CA 19 9 Antigen
- CA 19.9 Antigen
- Antigen, CA 19.9
- Gastrointestinal Cancer Antigen
- Cancer Antigen, Gastrointestinal
- CA 19-9 Antigen
- Antigen, CA 19-9
- Antigen CA-19-9
- Antigen CA 19 9
- CA-19-9, Antigen
|
Below are MeSH descriptors whose meaning is more general than "CA-19-9 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CA-19-9 Antigen".
This graph shows the total number of publications written about "CA-19-9 Antigen" by people in this website by year, and whether "CA-19-9 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2014 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "CA-19-9 Antigen" by people in Profiles.
-
Ono Y, Inoue Y, Ito H, Sasaki T, Takeda T, Ozaka M, Sasahira N, Hiratsuka M, Matsueda K, Oba A, Sato T, Saiura A, Takahashi Y. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels. HPB (Oxford). 2023 01; 25(1):100-108.
-
Pozzi Mucelli RM, Moro CF, Del Chiaro M, Valente R, Blomqvist L, Papanikolaou N, L?hr JM, Kartalis N. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria? Eur Radiol. 2022 Aug; 32(8):5144-5155.
-
Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, Ahrendt S, Gleisner A, Schulick RD, Del Chiaro M. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Ann Surg. 2022 01 01; 275(1):175-181.
-
Aoki S, Motoi F, Murakami Y, Sho M, Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients. BMC Cancer. 2019 Mar 21; 19(1):252.
-
Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M, Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg. 2019 Feb; 43(2):634-641.
-
Ateeb Z, Valente R, Pozzi-Mucelli RM, Malgerud L, Schlieper Y, Rangelova E, Fernandez-Moro C, L?hr JM, Arnelo U, Del Chiaro M. Main pancreatic duct dilation greater than 6?mm is associated with an increased risk of high-grade dysplasia and cancer in IPMN patients. Langenbecks Arch Surg. 2019 Feb; 404(1):31-37.
-
Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol. 2019 Feb; 54(2):194-203.
-
Jang JY, Park T, Lee S, Kim Y, Lee SY, Kim SW, Kim SC, Song KB, Yamamoto M, Hatori T, Hirono S, Satoi S, Fujii T, Hirano S, Hashimoto Y, Shimizu Y, Choi DW, Choi SH, Heo JS, Motoi F, Matsumoto I, Lee WJ, Kang CM, Han HS, Yoon YS, Sho M, Nagano H, Honda G, Kim SG, Yu HC, Chung JC, Nagakawa Y, Seo HI, Yamaue H. Proposed Nomogram Predicting the Individual Risk of Malignancy in the Patients With Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2017 12; 266(6):1062-1068.
-
Karabicak I, Satoi S, Yanagimoto H, Yamamoto T, Hirooka S, Yamaki S, Kosaka H, Inoue K, Matsui Y, Kon M. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016 Dec; 23(12):750-755.
-
Sadot E, Doussot A, O'Reilly EM, Lowery MA, Goodman KA, Do RK, Tang LH, G?nen M, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Allen PJ. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Ann Surg Oncol. 2015 Oct; 22(11):3512-21.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|